PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsOvarian cancer drug olaparib slows recurrence and cuts deaths

BioNews

Ovarian cancer drug olaparib slows recurrence and cuts deaths

Published 26 October 2018 posted in News and appears in BioNews 973

Author

Dr Loredana Guglielmi

PET BioNews

A drug to treat ovarian cancer has shown promising results in a clinical trial, delaying signs of relapse and reducing chances of death. The drug olaparib, a PARP inhibitor, was used in patients with BRCA-mutated advanced ovarian cancer...

A drug to treat ovarian cancer has shown promising results in a clinical trial, delaying signs of relapse and reducing chances of death. 

The phase III clinical trial, funded by AstraZeneca and Merck, assessed the efficacy of olaparib in 391 women with advanced ovarian cancer who had a BRCA gene mutation. Of these, 260 women treated with olaparib had a 70 percent reduced risk of cancer recurrence or death, compared with patients who did not receive the drug.

'The most exciting finding is that more than half the patients on the olaparib arm have not relapsed with a minimum of three years of follow-up,' said Professor Charlie Gourley, director of ovarian cancer research at the University of Edinburgh, which ran the British arm of the international trial.

'This is unprecedented and raises the possibility that a number of these patients may be cured, although longer follow-up of patients is required before we can definitively draw this conclusion.'

The study, published in The New England Journal of Medicine, showed that olaparib can be used as a maintenance and preventive therapy in patients who had already had chemotherapy or surgery, but showed no signs of disease relapse.

The majority of patients with ovarian cancer have no evidence of disease after ordinary treatment with surgery and chemotherapy, however approximately 70 percent have a relapse within three years. Recurrent ovarian cancer is typically incurable and represents a global unmet need, with around 7300 new cases every year in the UK.

Olaparib belongs to the class of PARP inhibitor drugs, so called because they block PARP proteins in cancer cells. PARP proteins prevent DNA damage in tumour cells carrying a BRCA mutation. Olaparib interferes with PARP molecules, causing an accumulation of DNA errors in cancer cells, ultimately leading to death of these cells. The drug is already approved in the USA and in Europe to treat advanced ovarian cancer that has returned after chemotherapy.

Dr Shibani Nicum, an oncologist at Oxford University Hospitals who was not involved in the study, said the findings were extremely important for women with newly diagnosed ovarian cancer and a BRCA mutation, 'raising the possibility of curing some women'.

Dr Nicum added: 'The future will be exciting as we determine how we might use olaparib and other PARP inhibitors to benefit a wider group of women.'

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
7 May 2021 • 2 minutes read

PARP inhibitor is most effective in ovarian cancer patients with DNA repair mutations

by Emma Bunting

New research suggests mutations in multiple DNA repair genes can determine how well ovarian cancer patients will respond to the PARP inhibitor, rucaparib...

PET BioNews
News
23 April 2021 • 2 minutes read

Olaparib extends life of ovarian cancer patients with BRCA1/2

by Hannah Flynn

Cancer treatment olaparib has been shown to extend the life of relapsed ovarian cancer patients with mutations in BRCA1 and BRCA2, by nearly 13 months, when used as a maintenance therapy...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
3 July 2020 • 2 minutes read

Breast cancer drug depletes ovarian reserve in mice

by Dr Rachael Boyle

A drug used to treated breast cancer has been shown to deplete stores of immature ovarian eggs in mice...

PET BioNews
News
29 May 2020 • 2 minutes read

Organoids used to study ovarian cancer

by Eleanor Mackle

Mini versions of mouse reproductive organs have been used to investigate how the most lethal ovarian cancers develop...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
20 March 2020 • 2 minutes read

Predicting patients benefits from new ovarian cancer treatment

by Jennifer Frosch

Analysing the tumour genome and cancer microenvironment can predict an ovarian cancer patient's response to a novel immune-PARP combination treatment, according to a new study...

PET BioNews
News
28 September 2018 • 2 minutes read

Contraceptive pill linked to lower risk of ovarian cancer

by Dr Maria Botcharova

Taking contraceptives that contain a low dose of oestrogen has been linked to a reduced rate of ovarian cancer, in a study of almost two million women...

PET BioNews
News
14 September 2018 • 2 minutes read

Simple urine test for early-stage ovarian cancer edges closer

by Isobel Steer

UK scientists have discovered a protein biomarker of early-stage ovarian cancer, which they hope will be detectable in a urine test...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
2 July 2018 • 2 minutes read

'Artificial ovary' for humans passes key milestone

by Shaoni Bhattacharya

Scientists have successfully supported human follicles — the precursors of egg cells — on a bioengineered ovarian 'scaffold' for the first time. The work is an important proof-of-concept, which may pave the way for developing artificial ovaries for

Leave a Reply Cancel reply

You must be logged in to post a comment.

« New CRISPR tool opens up more of the genome

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Common virus may be cause of recent hepatitis cases in children

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

1 August 2022 • 2 minutes read

CRISPR genome editing treatments may raise cancer risk

1 August 2022 • 2 minutes read

Differences in IVF-conceived children's size disappear by adolescence

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856